Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

RJ. Motzer, C. Porta, NJ. Vogelzang, CN. Sternberg, C. Szczylik, J. Zolnierek, C. Kollmannsberger, SY. Rha, GA. Bjarnason, B. Melichar, U. De Giorgi, V. Grünwald, ID. Davis, JL. Lee, E. Esteban, G. Urbanowitz, C. Cai, M. Squires, M. Marker, MM....

. 2014 ; 15 (3) : 286-96.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14063710
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 24556040
DOI 10.1016/s1470-2045(14)70030-0
Knihovny.cz E-zdroje

BACKGROUND: An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed as a mechanism of escape from VEGF-targeted therapies. Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma. METHODS: In this multicentre phase 3 study, patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor were randomly assigned through an interactive voice and web response system to receive open-label dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) or sorafenib (400 mg orally twice daily) in a 1:1 ratio. Randomisation was stratified by risk group and region. The primary endpoint was progression-free survival (PFS) assessed by masked central review. Efficacy was assessed in all patients who were randomly assigned and safety was assessed in patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01223027. FINDINGS: 284 patients were randomly assigned to the dovitinib group and 286 to the sorafenib group. Median follow-up was 11·3 months (IQR 7·9-14·6). Median PFS was 3·7 months (95% CI 3·5-3·9) in the dovitinib group and 3·6 months (3·5-3·7) in the sorafenib group (hazard ratio 0·86, 95% CI 0·72-1·04; one-sided p=0·063). 280 patients in the dovitinib group and 284 in the sorafenib group received at least one dose of study drug. Common grade 3 or 4 adverse events included hypertriglyceridaemia (38 [14%]), fatigue (28 [10%]), hypertension (22 [8%]), and diarrhoea (20 [7%]) in the dovitinib group, and hypertension (47 [17%]), fatigue (24 [8%]), dyspnoea (21 [7%]), and palmar-plantar erythrodysaesthesia (18 [6%]) in the sorafenib group. The most common serious adverse event was dyspnoea (16 [6%] and 15 [5%] in the dovitinib and sorafenib groups, respectively). INTERPRETATION: Dovitinib showed activity, but this was no better than that of sorafenib in patients with renal cell carcinoma who had progressed on previous VEGF-targeted therapies and mTOR inhibitors. This trial provides reference outcome data for future studies of targeted inhibitors in the third-line setting. FUNDING: Novartis Pharmaceuticals Corporation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063710
003      
CZ-PrNML
005      
20140708091635.0
007      
ta
008      
140704s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(14)70030-0 $2 doi
035    __
$a (PubMed)24556040
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Motzer, Robert J $u Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.
245    10
$a Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial / $c RJ. Motzer, C. Porta, NJ. Vogelzang, CN. Sternberg, C. Szczylik, J. Zolnierek, C. Kollmannsberger, SY. Rha, GA. Bjarnason, B. Melichar, U. De Giorgi, V. Grünwald, ID. Davis, JL. Lee, E. Esteban, G. Urbanowitz, C. Cai, M. Squires, M. Marker, MM. Shi, B. Escudier,
520    9_
$a BACKGROUND: An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed as a mechanism of escape from VEGF-targeted therapies. Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma. METHODS: In this multicentre phase 3 study, patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor were randomly assigned through an interactive voice and web response system to receive open-label dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) or sorafenib (400 mg orally twice daily) in a 1:1 ratio. Randomisation was stratified by risk group and region. The primary endpoint was progression-free survival (PFS) assessed by masked central review. Efficacy was assessed in all patients who were randomly assigned and safety was assessed in patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01223027. FINDINGS: 284 patients were randomly assigned to the dovitinib group and 286 to the sorafenib group. Median follow-up was 11·3 months (IQR 7·9-14·6). Median PFS was 3·7 months (95% CI 3·5-3·9) in the dovitinib group and 3·6 months (3·5-3·7) in the sorafenib group (hazard ratio 0·86, 95% CI 0·72-1·04; one-sided p=0·063). 280 patients in the dovitinib group and 284 in the sorafenib group received at least one dose of study drug. Common grade 3 or 4 adverse events included hypertriglyceridaemia (38 [14%]), fatigue (28 [10%]), hypertension (22 [8%]), and diarrhoea (20 [7%]) in the dovitinib group, and hypertension (47 [17%]), fatigue (24 [8%]), dyspnoea (21 [7%]), and palmar-plantar erythrodysaesthesia (18 [6%]) in the sorafenib group. The most common serious adverse event was dyspnoea (16 [6%] and 15 [5%] in the dovitinib and sorafenib groups, respectively). INTERPRETATION: Dovitinib showed activity, but this was no better than that of sorafenib in patients with renal cell carcinoma who had progressed on previous VEGF-targeted therapies and mTOR inhibitors. This trial provides reference outcome data for future studies of targeted inhibitors in the third-line setting. FUNDING: Novartis Pharmaceuticals Corporation.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a benzimidazoly $x škodlivé účinky $x terapeutické užití $7 D001562
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x mortalita $x sekundární $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x farmakoterapie $x mortalita $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a niacinamid $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D009536
650    _2
$a fenylmočovinové sloučeniny $x škodlivé účinky $x terapeutické užití $7 D010671
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a chinolony $x škodlivé účinky $x terapeutické užití $7 D015363
650    _2
$a vaskulární endoteliální růstový faktor A $x antagonisté a inhibitory $7 D042461
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Porta, Camillo $u Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo University Hospital Foundation, Pavia, Italy.
700    1_
$a Vogelzang, Nicholas J $u Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
700    1_
$a Sternberg, Cora N $u San Camillo and Forlanini Hospitals, Rome, Italy.
700    1_
$a Szczylik, Cezary $u Military Institute of Health Services in Warsaw, Warsaw, Poland.
700    1_
$a Zolnierek, Jakub $u Maria Sklodowska-Curie Institute, Warsaw, Poland.
700    1_
$a Kollmannsberger, Christian $u BC Cancer Agency Vancouver Cancer Centre, Vancouver, BC, Canada.
700    1_
$a Rha, Sun Young $u Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
700    1_
$a Bjarnason, Georg A $u Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
700    1_
$a Melichar, Bohuslav $u Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a De Giorgi, Ugo $u IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
700    1_
$a Grünwald, Viktor $u Hanover Medical School, Hanover, Germany.
700    1_
$a Davis, Ian D $u Monash University Eastern Health Clinical School, Melbourne, VIC, Australia.
700    1_
$a Lee, Jae-Lyun $u Asan Medical Center, Seoul, South Korea.
700    1_
$a Esteban, Emilio $u Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
700    1_
$a Urbanowitz, Gladys $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
700    1_
$a Cai, Can $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
700    1_
$a Squires, Matthew $u Novartis Pharma, Basel, Switzerland.
700    1_
$a Marker, Mahtab $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
700    1_
$a Shi, Michael M $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
700    1_
$a Escudier, Bernard $u Institut Gustave Roussy, Villejuif, France.
773    0_
$w MED00011558 $t The lancet oncology $x 1474-5488 $g Roč. 15, č. 3 (2014), s. 286-96
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24556040 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140708091925 $b ABA008
999    __
$a ok $b bmc $g 1031194 $s 862442
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 15 $c 3 $d 286-96 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20140704
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace